Menu Search
Equities

Malin Corporation PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0Y71:LSE

Malin Corporation PLC

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta0.1897
Data delayed at least 20 minutes, as of Jan 14 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Malin Corporation PLC is focused on investing in life sciences companies. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, WaveBreak, KNOW Bio, and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. KNOW Bio is a life science company engaged in the fields of nitric oxide and precision light therapy. WaveBreak Therapeutics company focuses on the development of medicines for the treatment of protein-misfolding diseases including Alzheimer's and Parkinson's. Artizan is a biotechnology company.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR0.00
  • Incorporated2014
  • Employees2.00
  • Location
    Malin Corporation PLCThe Lennox Building50 Richmond Street SouthDUBLIN D02 FK02IrelandIRL
  • Phone+353 19015700
  • Fax+353 19015701
  • Websitehttps://malinplc.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.